Recombinant human interleukin-3 in patients with hematopoietic failure.

Recombinant human interleukin-3 in patients with hematopoietic failure. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Recombinant human interleukin-3 in patients with hematopoietic failure. Abstract Text:

A Ganser,A Lindemann,G Seipelt,O G Ottmann,M Eder,F Herrmann,J Frisch,G Schulz,R Mertelsmann,D Hoelzer,

Nine patients with bone marrow failure and prolonged severe cytopenias were treated with recombinant human interleukin-3 (rhIL-3) at doses ranging from 30 micrograms/m2 to 500 micrograms/m2. rhIL-3 was administered in a subcutaneous bolus injection daily for 15 days. Platelet counts increased by a mean of 6-fold (range: 1.3- to 14.3-fold) in five out of eight evaluable patients. Reticulocyte counts increased 2.9-fold in three patients, and neutrophil counts increased by a mean of 3.1-fold in all eight patients. Platelet transfusions could be discontinued after treatment with rhIL-3 in two out of three evaluable transfusion-dependent patients. Only mild side effects, mainly fever and headache, were observed. These results indicate that rhIL-3 functions as a multilineage hematopoietic growth factor in vivo in patients with secondary bone marrow failure.

Recombinant human interleukin-3 in patients with hematopoietic failure. Publishing Authors By Initials

A Ganser,A Lindemann,G Seipelt,OG Ottmann,M Eder,F Herrmann,J Frisch,G Schulz,R Mertelsmann,D Hoelzer,

For similar proteins: recombinant proteins research abstracts see: proteins: recombinant proteins research

PUBMED ID PMID:

MEDLINE DATE:

Recombinant human interleukin-3 in patients with hematopoietic failure. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Recent results in cancer research. Fortschritte de

VOLUME: 121

Page Numbers: 162-72

Journal Abbreviation: Recent Results Cancer Res.

ISSN: 0080-0015

DAY: 13

MONTH: 02

YEAR: 1991

Recombinant human interleukin-3 in patients with hematopoietic failure. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 44671

Recombinant human interleukin-3 in patients with hematopoietic failure. Keywords Mesh Terms:

KEYWORDS: Recombinant Proteins

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Recombinant human interleukin-3 in patients with hematopoietic failure. Information

Substance Name: Recombinant Proteins

Registry Number: 0

Grant and Affiliation Information for Recombinant human interleukin-3 in patients with hematopoietic failure.

AFFILIATION: Abteilung für Hämatologie, Johann Wolfgang Goethe-Universität, Frankfurt, FRG.

Country: GERMANY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Recent Results Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Recombinant human interleukin-3 in patients with hematopoietic failure Related Publications

• Current status of ALL/AUL therapy in adults.
• Cytobiology and clinical findings of myelodysplastic syndromes.
• Hemopoietic growth factors in the treatment of acute leukemias and myelodysplastic syndromes.
• High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma : comparison of results in human immunodeficiency virus-infected and noninfected patients.
• Recombinant human interleukin-3 in patients with hematopoietic failure.
• [Antibiotic therapy in leukopenia]
• [Growth factors in oncology: effectiveness and prospects]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Treatment of adult acute lymphoblastic leukemia]